OMERS ADMINISTRATION Corp Invests $381,000 in Sensus Healthcare, Inc. (NASDAQ:SRTS)

OMERS ADMINISTRATION Corp acquired a new stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 55,100 shares of the company's stock, valued at approximately $381,000. OMERS ADMINISTRATION Corp owned 0.34% of Sensus Healthcare at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of SRTS. JPMorgan Chase & Co. bought a new position in Sensus Healthcare during the fourth quarter valued at $27,000. Barclays PLC bought a new position in Sensus Healthcare during the fourth quarter valued at $35,000. BNP Paribas Financial Markets bought a new position in Sensus Healthcare during the fourth quarter valued at $47,000. IFP Advisors Inc bought a new position in Sensus Healthcare during the fourth quarter valued at $95,000. Finally, NewEdge Advisors LLC bought a new position in Sensus Healthcare during the fourth quarter valued at $109,000. 25.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Sensus Healthcare in a report on Friday, April 4th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Thursday. Maxim Group cut their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Lake Street Capital cut their price target on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.67.

Sensus Healthcare Price Performance

SRTS stock traded up $0.01 during mid-day trading on Friday, hitting $4.69. 41,205 shares of the stock were exchanged, compared to its average volume of 208,082. The business has a fifty day moving average price of $4.61 and a 200 day moving average price of $6.05. Sensus Healthcare, Inc. has a 12 month low of $4.01 and a 12 month high of $9.33. The stock has a market capitalization of $77.13 million, a price-to-earnings ratio of 11.73 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The firm had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. As a group, equities analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.